Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Stays Committed To Alzheimer's, Including Amyloid Hypothesis, Despite Many Failures

Executive Summary

The failure of BACE inhibitor lanabecestat was the latest setback in Lilly's Alzheimer's pipeline, but the company has been working in this area with almost no success for decades, yet still feels a commitment to keep trying, Lilly Research Labs President Daniel Skovronsky tells Scrip.

Advertisement

Related Content

Eisai/Biogen Remain In BACE Race As Alzheimer's Contenders Dwindle
M&A Pressure Mounts For Merck & Co After Alzheimer's Drug Dismissed
Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success
Alzheimer's Disease: Learning the Lessons Of The Past To Prepare For The Future
Lilly ends Phase III development of gamma secretase inhibitor for Alzheimer's

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123255

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel